Numinus Competitors

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

Mindbloom offers guided at-home ketamine therapy to transform your mental health. Together with medical leaders in the field, we have created a best-in-class treatment program that is driving transformational outcomes for our clients. It’s a new day for mental health, and the future looks bright. We have an award-winning company, culture, and leadership team: * Top 150 Digital Health Startups — CB Insights * 50 Best Remote-First Companies to Work For in 2021 — BuiltIn * Top 25 Consumer Healthcare Executives in 2020 — The Healthcare Technology Report *2022 Tony Hsieh Award for most transformational cultures *22 Remote Startups to Watch in 2022 *29 Telemedicine Companies to Know We're backed by Tier 1 VC's, and we're on a mission to transform lives to transform the world. Join us! **Spam alert** It’s been brought to our attention that a spam account has been emailing Mindbloom applicants asking that an app be downloaded to apply for open Mindbloom positions. These messages are currently being sent from support@mindbloom.site. Please note that our team will not ask anyone to download an app. All correspondence from the Mindbloom team will come directly from a mindbloom.com email address. We apologize for any confusion. Stay safe!

MindMed is now Definium Therapeutics, a rebrand that reflects our commitment to forging a new era of psychiatry by applying precision to psychedelic medicine. Follow our new page at the link below!